摘要
目的分析左甲状腺素钠片(商品名:优甲乐)对甲状腺功能减退患者甲状腺功能的影响。方法84例甲状腺功能减退患者,依据数字表法分为对照组与观察组,每组42例。对照组患者给予口服甲状腺片治疗,观察组在对照组基础上联合优甲乐治疗。比较两组治疗效果、治疗前后生存质量及甲状腺功能指标[游离三碘甲状腺原氨酸(FT_(3))、游离甲状腺素(FT_(4))、促甲状腺激素(TSH)]。结果观察组治疗总有效率92.86%高于对照组的76.19%,差异有统计学意义(P<0.05)。治疗后,观察组生存质量评分(85.51±6.24)分高于对照组的(72.51±3.12)分,差异有统计学意义(P<0.05)。治疗后,观察组FT_(3)、FT_(4)水平分别为(6.82±2.21)、(13.45±2.22)pmol/L高于对照组的(4.85±1.44)、(10.23±1.67)pmol/L,TSH水平(4.45±1.35)mU/L低于对照组的(8.15±2.10)mU/L,差异均有统计学意义(P<0.05)。结论优甲乐在甲状腺功能减退治疗中的效果确切,可有效改善患者甲状腺功能,促进生存质量提高,值得临床推广应用。
Objective To analyze the effect of levothyroxine sodium tablets(trade name:Euthyrox)on thyroid function of patients with hypothyroidism.Methods A total of 84 patients with hypothyroidism were divided into control group and observation group according to the digital table method,with 42 cases in each group.Patients in the control group were treated with oral administration of thyroid tablets,and patients in the observation group were treated with Euthyrox on the basis of the treatment in the control group.The therapeutic effect,quality of life and thyroid function indexes[free triiodothyronine(FT3),free thyroxine(FT4),thyroid stimulating hormone(TSH)]before and after treatment were compared between the two groups.Results The total effective rate 92.86%of the observation group was higher than 76.19%of the control group,and the difference was statistically significant(P<0.05).After treatment,the quality of life score(85.51±6.24)points in the observation group was higher than(72.51±3.12)points in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of FT3 and FT4 in the observation group were(6.82±2.21)and(13.45±2.22)pmol/L,which were higher than(4.85±1.44)and(10.23±1.67)pmol/L in the control group,and the level of TSH(4.45±1.35)mU/L was lower than(8.15±2.10)mU/L in the control group.All the differences were statistically significant(P<0.05).Conclusion Euthyrox has definite effect in the treatment of hypothyroidism,and can effectively improve the thyroid function of patients and promote the improvement of quality of life,which is worthy of clinical promotion and application.
作者
倪萍
李松
张慧
NI Ping;LI Song;ZHANG Hui(Endocrine Department,Wafangdian Central Hospital,Wafangdian 116300,China)
出处
《中国现代药物应用》
2022年第9期137-140,共4页
Chinese Journal of Modern Drug Application
